Lyell Immunopharma Inc.

11/04/2023 | Press release | Distributed by Public on 11/04/2023 10:50

SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective[...]